Drugs including ceritinib, alectinib, and brigatinib have been developed to treat cancers with mutations in the ALK gene, including lung cancer and NB, demonstrating a higher efficacy than older drugs like crizotinib, especially against specific ALK mutations. Here, ALK is linked to lung carcinoma.